FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 631 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading ESMO Welcomes European Parliament Resolution Marking World Cancer Day MOST POPULAR TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer March 7, 2025 Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... June 21, 2023 Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... November 30, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide August 9, 2024 Load more HOT NEWS Better together: improving brain tumour treatment Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... Navigating Cancer Survivorship as a Transgender or Non-Binary Person Study Suggests Statins May Help Keep Breast Cancer from Spreading to...
